Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
Bio-IT World September 2006 Kevin Davies	Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.
Bio-IT World January 21, 2005	Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Bio-IT World May 19, 2004 John Russell	Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT.
Bio-IT World August 18, 2004 John Russell	Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy.
Bio-IT World November 14, 2003 Malorye Branca	Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines.
Bio-IT World November 12, 2002 Michael Goldman	A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?
Bio-IT World December 15, 2003 Malorye A. Branca	Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful.
Bio-IT World April 16, 2004 Malorye Branca	Finding the Perfect Fit Fragment-based drug discovery is unique and effective.
Bio-IT World October 10, 2003 Donna Mendrick	Microarrays That Make Drugs Safe Using DNA chips to discover potential toxicity in new drug compounds -- a key application of toxicogenomics -- can predict adverse effects before they occur, enabling safer clinical trials.
Bio-IT World March 10, 2003 Mark D. Uehling	Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together.
Bio-IT World August 13, 2003 Malorye Branca	Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.
Chemistry World August 13, 2015	Exploiting the data mine Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, reports Clare Sansom
Bio-IT World April 2007 Vicki Glaser	Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.
Chemistry World February 2011	Idle cures Taking a coffee break could help find cures for cancer or Aids. Katrina Megget looks at the future of research that harnesses the computing power of the World Community Grid
Bio-IT World Jul/Aug 2006 Eric K. Neumann	Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done?
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
Industrial Physicist Jennifer Ouellette	Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems
Bio-IT World June 17, 2004 Mark D. Uehling	How to Spell Discovery Rapidly combining cosmos of chemical and biological data, Johnson & Johnson's multidisciplinary ABCD platform for drug discovery aims to give scientists access to more information -- and the ability to make better decisions
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Wired August 2003 Jennifer Kahn	The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine.
ONLINE Sep/Oct 2007 Svetla Baykoucheva	A New Era in Chemical Information: PubChem, DiscoveryGate, and Chemistry Central How the emergence of PubChem, DiscoveryGate and Chemistry Central are changing the field of chemical information.
Bio-IT World December 10, 2002 Hillel Alpert	Bio-IT Shines Bright in Israel Companies such as Quark and Pharmos are still flourishing as other industries decline in this country torn by conflict.
Bio-IT World July 11, 2002 Malorye Branca	Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed.
Bio-IT World April 15, 2003 Malorye Branca	Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Bio-IT World March 2007 Kevin Davies	Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges.
Bio-IT World January 13, 2003 Michael Gross	Profiting from the Proteome Inpharmatica sells data products, but it also wants to discover drugs.
Chemistry World September 29, 2015	Navigating chemical space How big is chemistry? I don't mean how important is it, or how many people do it, but rather, how many molecules are there that we could make?
Fast Company November 2010 Elizabeth Svoboda	The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs.
Bio-IT World September 2006 Mike May	Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.
Bio-IT World November 19, 2004 Kevin Davies	De-Lovely Pharmaceuticals De Novo Pharmaceuticals identifies novel compounds right before your eyes.
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
HHMI Bulletin Nov 2011 Sarah C. P. Williams	Living Chemistry Biologists understand better what chemists can bring to the table. And chemists understand better the questions that biologists really care about. This has led to a bigger impact of chemists on biological problems.
Bio-IT World September 11, 2003 Mark D. Uehling	Fishing Chips The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may threaten the early leads of Biacore and Ciphergen -- and work so well that drug companies won't want them.
Bio-IT World August 13, 2002 Malorye Branca	The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed?
Bio-IT World September 2006 John A. Wass	Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem.
Chemistry World May 18, 2010 Sarah Houlton	EPA and pharma join forces The US Environmental Protection Agency is working with pharmaceutical companies to improve its ToxCast toxicity prediction tool.
Bio-IT World August 18, 2004	Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Knowledge@Wharton	A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies...
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.